• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

研究基因组和表观基因组数据以了解前列腺癌。

Interrogating genomic and epigenomic data to understand prostate cancer.

作者信息

Kim Jung, Yu Jindan

机构信息

Division of Hematology/Oncology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.

出版信息

Biochim Biophys Acta. 2012 Apr;1825(2):186-96. doi: 10.1016/j.bbcan.2011.12.003. Epub 2012 Jan 3.

DOI:10.1016/j.bbcan.2011.12.003
PMID:22240201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3307852/
Abstract

Major breakthroughs at the beginning of this century in high-throughput technologies have profoundly transformed biological research. Significant knowledge has been gained regarding our biological system and its disease such as malignant transformation. In this review, we summarize leading discoveries in prostate cancer research derived from the use of high-throughput approaches powered by microarrays and massively parallel next-generation sequencing (NGS). These include the seminal discovery of chromosomal translocations such as TMPRSS2-ERG gene fusions as well as the identification of critical oncogenes exemplified by the polycomb group protein EZH2. We then demonstrate the power of interrogating genomic and epigenomic data in understanding the plethora of mechanisms of transcriptional regulation. As an example, we review how androgen receptor (AR) binding events are mediated at multiple levels through protein-DNA interaction, histone and DNA modifications, as well as high-order chromatin structural changes.

摘要

本世纪初高通量技术的重大突破深刻改变了生物学研究。我们对生物系统及其疾病(如恶性转化)已有了大量认识。在本综述中,我们总结了前列腺癌研究中的主要发现,这些发现源自使用由微阵列和大规模平行下一代测序(NGS)驱动的高通量方法。其中包括诸如TMPRSS2-ERG基因融合等染色体易位的开创性发现,以及以多梳蛋白家族蛋白EZH2为代表的关键致癌基因的鉴定。然后,我们展示了在理解转录调控的众多机制方面,研究基因组和表观基因组数据的作用。例如,我们回顾了雄激素受体(AR)结合事件如何通过蛋白质-DNA相互作用、组蛋白和DNA修饰以及高阶染色质结构变化在多个层面上介导。

相似文献

1
Interrogating genomic and epigenomic data to understand prostate cancer.研究基因组和表观基因组数据以了解前列腺癌。
Biochim Biophys Acta. 2012 Apr;1825(2):186-96. doi: 10.1016/j.bbcan.2011.12.003. Epub 2012 Jan 3.
2
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.雄激素受体、多梳、TMPRSS2-ERG 基因融合在前列腺癌进展中的整合网络。
Cancer Cell. 2010 May 18;17(5):443-54. doi: 10.1016/j.ccr.2010.03.018.
3
TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.通过易位或间质性缺失形成的TMPRSS2:ERG融合在雄激素依赖性前列腺癌中高度相关,但在晚期雄激素受体阴性前列腺癌中则不存在。
Cancer Res. 2006 Nov 15;66(22):10658-63. doi: 10.1158/0008-5472.CAN-06-1871.
4
Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.ETS 转录因子家族成员 ERG、雄激素受体和拓扑异构酶 2β 的表达与前列腺癌中 TMPRSS2-ERG 融合状态的关系。
Neoplasma. 2014;61(1):9-16.
5
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.雄激素诱导的非恶性前列腺上皮细胞中的 TMPRSS2:ERG 融合。
Cancer Res. 2010 Dec 1;70(23):9544-8. doi: 10.1158/0008-5472.CAN-10-1638. Epub 2010 Oct 14.
6
A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome.高分辨率 3D 表观基因组图谱揭示了前列腺癌转录组形成的见解。
Nat Commun. 2019 Sep 12;10(1):4154. doi: 10.1038/s41467-019-12079-8.
7
Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.FAM3B 与雄激素受体之间反馈调节的丧失驱动前列腺癌的进展。
J Natl Cancer Inst. 2024 Mar 7;116(3):421-433. doi: 10.1093/jnci/djad215.
8
CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.CCN3/NOV 基因在人类前列腺癌中的表达受雄激素受体的直接抑制。
Oncogene. 2014 Jan 23;33(4):504-13. doi: 10.1038/onc.2012.602. Epub 2013 Jan 14.
9
Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.雄激素受体基因拷贝数增加与前列腺小细胞癌中的TMPRSS2-ERG重排相关。
Mol Carcinog. 2015 Sep;54(9):900-7. doi: 10.1002/mc.22162. Epub 2014 Apr 29.
10
Recurrent rearrangements in prostate cancer: causes and therapeutic potential.前列腺癌中的反复重排:原因和治疗潜力。
Curr Drug Targets. 2013 Apr;14(4):450-9. doi: 10.2174/1389450111314040006.

引用本文的文献

1
Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review.用于前列腺癌风险评估的基因表达谱分析趋势:一项系统综述。
Biomed Hub. 2017 May 17;2(2):1-15. doi: 10.1159/000472146. eCollection 2017 May-Aug.
2
Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.EZH2通过miR-181b/HK2轴参与前列腺癌的有氧糖酵解过程。
Oncol Rep. 2017 Mar;37(3):1430-1436. doi: 10.3892/or.2017.5430. Epub 2017 Feb 7.
3
Cancer Prognosis Defined by the Combined Analysis of 8q, PTEN and ERG.通过8q、PTEN和ERG联合分析定义的癌症预后
Transl Oncol. 2016 Dec;9(6):575-582. doi: 10.1016/j.tranon.2016.08.005.
4
H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.H3K27甲基化:癌症中表观遗传失调的焦点
Adv Cancer Res. 2016;131:59-95. doi: 10.1016/bs.acr.2016.05.001. Epub 2016 Jun 17.
5
Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.ERG过表达和野生型PTEN与前列腺癌良好的临床预后及低生化复发相关。
PLoS One. 2015 Apr 21;10(4):e0122498. doi: 10.1371/journal.pone.0122498. eCollection 2015.
6
Autoinhibitory mechanisms of ERG studied by molecular dynamics simulations.通过分子动力学模拟研究ERG的自抑制机制。
AIP Adv. 2015 Jan 22;5(1):017130. doi: 10.1063/1.4906572. eCollection 2015 Jan.
7
Prostate cancer epigenome.前列腺癌表观基因组
Methods Mol Biol. 2015;1238:125-40. doi: 10.1007/978-1-4939-1804-1_7.
8
Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.分子途径:癌症中组蛋白H3赖氨酸27甲基化的失调——路径不同,终点相同。
Clin Cancer Res. 2014 Oct 1;20(19):5001-8. doi: 10.1158/1078-0432.CCR-13-2499. Epub 2014 Jul 1.
9
Prostate cancer epigenetic biomarkers: next-generation technologies.前列腺癌表观遗传生物标志物:新一代技术
Oncogene. 2015 Mar 26;34(13):1609-18. doi: 10.1038/onc.2014.111. Epub 2014 May 19.
10
Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.维持和重新编程前列腺癌中的基因组雄激素受体活性。
Nat Rev Cancer. 2014 Mar;14(3):187-98. doi: 10.1038/nrc3678.

本文引用的文献

1
The three-dimensional architecture of a bacterial genome and its alteration by genetic perturbation.细菌基因组的三维结构及其遗传扰动的改变。
Mol Cell. 2011 Oct 21;44(2):252-64. doi: 10.1016/j.molcel.2011.09.010.
2
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.雄激素受体基因在前列腺癌中的表达被雄激素受体直接抑制,通过募集赖氨酸特异性去甲基化酶 1。
Cancer Cell. 2011 Oct 18;20(4):457-71. doi: 10.1016/j.ccr.2011.09.001.
3
Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells.雄激素受体增强子在前列腺癌细胞中无配体时的动态核小体缺失区域。
Mol Cell Biol. 2011 Dec;31(23):4648-62. doi: 10.1128/MCB.05934-11. Epub 2011 Oct 3.
4
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.外显子组测序鉴定了晚期和致命前列腺癌中一系列突变频率。
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17087-92. doi: 10.1073/pnas.1108745108. Epub 2011 Sep 26.
5
A decade of exploring the cancer epigenome - biological and translational implications.一个探索癌症表观基因组的十年 - 生物学和转化意义。
Nat Rev Cancer. 2011 Sep 23;11(10):726-34. doi: 10.1038/nrc3130.
6
FOXA1: master of steroid receptor function in cancer.FOXA1:癌症中甾体激素受体功能的主宰者。
EMBO J. 2011 Sep 20;30(19):3885-94. doi: 10.1038/emboj.2011.340.
7
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.FoxA1 在雄激素受体与染色质结合、雄激素信号传导和前列腺癌中的双重作用。
EMBO J. 2011 Sep 13;30(19):3962-76. doi: 10.1038/emboj.2011.328.
8
Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.定义 FoxA1 顺式作用元件,对于去势抵抗性前列腺癌中 G1 期到 S 期细胞周期转换至关重要。
Cancer Res. 2011 Nov 1;71(21):6738-6748. doi: 10.1158/0008-5472.CAN-11-1882. Epub 2011 Sep 7.
9
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers.在组织干细胞/祖细胞区室以及人类癌症中,整体5-羟甲基胞嘧啶含量显著降低。
Oncotarget. 2011 Aug;2(8):627-37. doi: 10.18632/oncotarget.316.
10
Androgen receptor-driven chromatin looping in prostate cancer.雄激素受体驱动的前列腺癌染色质环化。
Trends Endocrinol Metab. 2011 Dec;22(12):474-80. doi: 10.1016/j.tem.2011.07.006. Epub 2011 Aug 31.